EBI (US) goes it alone after Orthofix (Italy) agreement ends
This article was originally published in Clinica
Biomet's EBI subsidiary (US) will develop its own advanced fixation system following the ending of an agreement with its supplier, Orthofix (Italy). The deal expires at the end of May 1995. Orthofix is to acquire American Medical Electronics and gain its US sales force (see Clinica No 654, p 12) for $79 million, a company in which Biomet owns 6% of outstanding shares.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.